Subscribe to this collection to receive daily e-mail notification of new additions

Publication Year	Title	Author(s)
2019	CERAMIDE EVOKES AN APOPTOTIC INTEGRATED STRESS RESPONSE IN ACUTE MYELOID LEUKEMIA	Craig Wallington-Gates ; Jason Powell; Alexander Lewis; Melinda Tea; Thao Nguyen; Dovile Anderson; Darren Creek; Richard D'Andrea; David Ross; Daniel Thomas; Stuart Pitson
Oct-2019	Sphingolipids and the unfolded protein response	Bennett, Melissa K; Wallington-Gates, Craig ; Pitson, Stuart M
2021	Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma	Craig Wallington-Gates ; Lisa M. Ebert; Kate Vandyke; M. Zahied Johan; Mark DeNichilo; Lih Y. Tan; Kay K. Myo Min; Benjamin M. Weimann; Brenton W. Ebert; Stuart M. Pitson; Andrew C. W. Zannettino; Claudine S. Bonder
11-Jun-2021	Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma	Mynott, Rachel L; Wallington-Gates, Craig
28-Aug-2017	Novel therapies for multiple myeloma	Wallington-Gates, Craig ; Pitson, Stuart M
30-Jun-2022	Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia	Lewis, Alexander C; Pope, Victoria S; Tea, Melinda N; Li, Manjun; Nwosu, Gus O; Nguyen, Thao M; Wallington-Gates, Craig ; Moretti, Paul A B; Anderson, Dovile; Creek, Darren J; Costabile, Maurizio; Ali, Saira R; Thompson-Peach, Chloe A L; Dredge, B Kate; Bert, Andrew G; Goodall, Gregory J; Ekert, Paul G; Brown, Anna L; D'Andrea, Richard; Robinson, Nirmal; Pitman, Melissa R; Thomas, Daniel; Ross, David M; Gliddon, Briony L; Powell, Jason A; Pitson, Stuart M
2019	INHIBITION OF SPHINGOSINE KINASE 2 RESENSITISES BORTEZOMIB-RESISTANT MULTIPLE MYELOMA	Melissa Bennett; Melinda Tea; Briony Gliddon; John Toubia; Robert Orlowski; Craig Wallington-Beddoe ; Stuart Pitson
2023	Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies	Rachel L Mynott; Ali Habib; Giles Best; Craig Wallington-Gates
2020	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial	Grosicki, S.; Simonova, M.; Spicka, I.; Pour, L.; Kriachok, I.; Gavriatopoulou, M.; Pylypenko, H.; Auner, H.W.; Leleu, X.; Doronin, V.; Usenko, G.; Bahlis, N.J.; Hajek, R.; Benjamin, R.; Dolai, T.K.; Sinha, D.K.; Venner, C.P.; Garg, M.; Gironella, M.; Jurczyszyn, A.; Robak, P.; Galli, M.; Wallington-Gates, Craig Thomas ; Radinoff, A.; Salogub, G.; Stevens, D.A.; Basu, S.; Liberati, A.M.; Quach, H.; Goranova-Marinova, V.S.; Bila, J.; Katodritou, E.; Oliynyk, H.; Korenkova, S.; Kumar, J.; Jagannath, S.; Moreau, P.; Levy, M.; White, D.; Gatt, M.E.; Facon, T.; Mateos, M.V.; Cavo, M.; Reece, D.; Anderson, L.D.; Saint-Martin, J.-R.; Jeha, J.; Joshi, A.A.; Chai, Y.; Li, L.; Peddagali, V.; Arazy, M.; Shah, J.; Shacham, S.; Kauffman, M.G.; Dimopoulos, M.A.; Richardson, P.G.; Delimpasi, S.
2021	Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)	Craig Wallington-Gates
2021	Prognostic and Therapeutic Biomarker Developments in Multiple Myeloma	Wallington-Gates, Craig Thomas ; Mynott, R.L.
2003	Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting	Kumar, D.; Wallington-Gates, Craig Thomas ; George, Joanne ; Lin, R.; Samarasinghe, D.; Liddle, C.; Farrell, G.C.
2018	Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis	Craig Wallington-Gates
2017	Enhancing ER stress in myeloma	Wallington-Gates, Craig Thomas ; Pitson, S.M.
2022	Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition	Craig Wallington-Gates
2019	Resistance Mechanisms to Novel Therapies in Myeloma	Craig Wallington-Gates ; Douglas Coghlan
2017	Targeting Sphingosine Kinase 1 in Acute Myeloid Leukemia: Translation to the Clinic	Jason Powell; Craig Wallington-Gates ; Stuart Pitson
2013	Oncogenic properties of sphingosine kinases in haematological malignancies	Wallington-Gates, Craig ; Bradstock, KF; Bendall, LJ
2017	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia	Powell, JA; Lewis, A; Zhu, W; Toubia, J; Pitman, MR; Wallington-Gates, Craig ; Moretti, PA; Larossi, D; Samaraweera, SE; Cummings, N; Ramshaw, HS; Thomas, D; Wei, AH; Lopez, AF; Richardson, AJ; Lewis, ID; Pitson, SM
2017	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress	Wallington-Gates, Craig ; Bennett, MK; Vandyke, K; Davies, L; Zebol, JR; Moretti, PA; Hewett, DR; Zannettino, AC; Pitson, SM